Allergan plc (AGN)

NYSE - NYSE Real Time Price. Currency in USD
221.99-3.30 (-1.46%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close225.29
Bid221.50 x 100
Ask240.00 x 1000
Day's Range221.83 - 226.53
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap87.9B
P/E Ratio (ttm)21.14
Avg Vol (3m)3,301,864
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire13 minutes ago

    Allergan to Acquire GI Disease Subsidiary of Rhythm Holding Company, LLC, Expanding Innovative Gastroenterology Pipeline

    DUBLIN and BOSTON, Oct. 27, 2016 /PRNewswire/ -- Allergan plc. (AGN), a leading global pharmaceutical company and Rhythm Holding Company, LLC, which owns Motus Therapeutics, Inc. a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) disorders, announced today the top line results of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Motus' ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. Allergan also announced that it has exercised its option to acquire Motus Therapeutics.  Motus (formerly known as Rhythm Health) is a wholly-owned subsidiary of Rhythm Holding Company, LLC.

  • PR Newswire15 hours ago

    Allergan Announces Changes to Board Leadership

    DUBLIN, Oct. 26, 2016 /PRNewswire/ -- Allergan plc (AGN) today announced changes to leadership roles within its board of directors.  Effective today, Brenton L. Saunders has been elected Chairman of the Allergan's Board of Directors replacing Paul Bisaro, who served as Executive Chairman since July 1, 2014.  Bisaro will remain a member of the Allergan Board of Directors.  In addition to the role of Chairman, Saunders will retain his current role as Chief Executive Officer and President.  Also, effective today, Christopher Coughlin has been elected Lead Independent Director.

  • American City Business Journals19 hours ago

    $690M done deal: Allergan completes Vitae acquisition

    Allergan successfully completed its tender offer for all the outstanding shares of Vitae Pharmaceuticals Inc., a clinical-stage biopharmaceutical company based in Fort Washington, Pennsylvania. Under the terms of the $639 million deal, Allergan (AGN) paid Vitae stockholders $21 per share. “The completion of the Vitae acquisition will add highly differentiated development compounds and bolsters our innovative medical dermatology pipeline,” said David Nicholson, chief research and development officer at Allergan.